Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 8/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30869827 | 0.75 | KDM1A (0.64) | MAPTSMN1; SMN2GAAKDM1AL3MBTL1 | |
| SCHEMBL31388396 | 0.75 | SMN1; SMN2 (0.54) | MAPTSMN1; SMN2 | |
| SCHEMBL5214087 | 0.74 | NOX1 (0.37) | MAPTSMN1; SMN2KDM1AKDM4EL3MBTL1 | |
| SCHEMBL5215376 | 0.73 | DRD2 (0.43) | MAPTSMN1; SMN2KDM4ESIGMAR1ALDH1A1 | |
| SCHEMBL31388397 | 0.71 | EPHX2 (0.59) | MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL5253886 | 0.71 | GAA (0.38) | MAPTSMN1; SMN2GAAKDM4EL3MBTL1 | |
| SCHEMBL5219441 | 0.71 | HTR2A (0.37) | L3MBTL1ALDH1A1 | |
| SCHEMBL31388393 | 0.71 | EPHX2 (0.59) | GAA | |
| SCHEMBL5256493 | 0.70 | EHMT2 (0.38) | MAPTSMN1; SMN2L3MBTL1SIGMAR1ALDH1A1 | |
| SCHEMBL5185925 | 0.68 | CYP2D6 (0.51) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539724-B1 | AMINO BENZOTHIAZOLE COMPOUNDS WITH NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2007-10-10 | — | — | EP | disclosed |
| US-7141595-B2 | Amino benzothiazole compounds with NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-28 | — | — | US | disclosed |
| US-20050209291-A1 | N-(2-Amino-benzothiazol-6-yl)-ethylthiocarboximidamide or other amino benzothiazole derivatives as neuroprotectants and for the treatment of neuropathic pain | NEURAXON INC. (CA) | 2005-09-22 | — | — | US | disclosed |
| EP-1539724-A1 | AMINO BENZOTHIAZOLE COMPOUNDS WITH NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004014885-A1 | AMINO BENZOTHIAZOLE COMPOUNDS WITH NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209291-A1 | N-(2-Amino-benzothiazol-6-yl)-ethylthiocarboximidamide or other amino benzothiazole derivatives as neuroprotectants and for the treatment of neuropathic pain | GAP43, NLN, TRPV1 | MAPT 1123/4885SMN1; SMN2 71/4885GAA 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.